Overview

Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma

Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether compared with arsenic trioxide TACE alone, arsenic trioxide TACE and intravenous administration could further prolong the overall survival.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Guangdong General Hospital
Guangdong Provincial People's Hospital
Treatments:
Arsenic Trioxide
Chlorotrianisene
Ethiodized Oil
Pharmaceutical Solutions